X4 Pharmaceuticals Valuation
| XFOR Stock | USD 0.51 0.05 10.87% |
X4 Pharmaceuticals is undervalued. X4 Pharmaceuticals owns a latest Real Value of $1.13 per share. The recent price of the entity is $0.51. Our model calculates the value of X4 Pharmaceuticals from inspecting the entity fundamentals such as return on asset of -0.4, and Shares Owned By Insiders of 1.14 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting X4 Pharmaceuticals' valuation include:
Price Book 1.3193 | Enterprise Value | Enterprise Value Ebitda 1.1003 | Price Sales 153.764 | Enterprise Value Revenue 19.4853 |
Undervalued
Today
Please note that X4 Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of X4 Pharmaceuticals is based on 3 months time horizon. Increasing X4 Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the XFOR stock is determined by what a typical buyer is willing to pay for full or partial control of X4 Pharmaceuticals. Since X4 Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XFOR Stock. However, X4 Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.51 | Real 1.13 | Target 3.08 | Hype 0.49 |
The intrinsic value of X4 Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence X4 Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of X4 Pharmaceuticals helps investors to forecast how XFOR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of X4 Pharmaceuticals more accurately as focusing exclusively on X4 Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use X4 Pharmaceuticals' intrinsic value based on its ongoing forecasts of X4 Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against X4 Pharmaceuticals' closest peers.
X4 Pharmaceuticals Cash |
|
XFOR Valuation Trend
X4 Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of X4 Pharmaceuticals' financial worth over time. Using both X4 Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
X4 Pharmaceuticals Total Value Analysis
X4 Pharmaceuticals is at this time estimated to have valuation of 21.88 M with market capitalization of 86.57 M, debt of 58.28 M, and cash on hands of 47.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the X4 Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.88 M | 86.57 M | 58.28 M | 47.38 M |
X4 Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of XFOR is to check how much profit was generated for every dollar of assets it reports. X4 Pharmaceuticals owns a negative utilization of current and long term assets of -0.4 %, losing $0.004023 for each dollar of current and long term assets held by the entity. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of X4 Pharmaceuticals shows how wasteful it operates for each dollar spent on its current and long term assets.X4 Pharmaceuticals Ownership Allocation
X4 Pharmaceuticals secures a total of 170.55 Million outstanding shares. Over half of X4 Pharmaceuticals' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.X4 Pharmaceuticals Profitability Analysis
Net Loss for the year was (101.17 M) with profit before overhead, payroll, taxes, and interest of 295 K.About X4 Pharmaceuticals Valuation
The stock valuation mechanism determines X4 Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of X4 Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of X4 Pharmaceuticals. We calculate exposure to X4 Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of X4 Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.8 M | -1.7 M | |
| Pretax Profit Margin | (23.76) | (24.95) | |
| Operating Profit Margin | (22.95) | (24.10) | |
| Net Loss | (23.82) | (25.01) | |
| Gross Profit Margin | 0.87 | 0.78 |
X4 Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as X4 Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 177.8 M |
X4 Pharmaceuticals Current Valuation Indicators
X4 Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final X4 Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as X4 Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use X4 Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes X4 Pharmaceuticals' worth.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.